@article{817d4710e8aa4ad8be834b8df40f2779,
title = "Concomitant administration of interleukin-2 during therapeutic vaccinations against cancer: The good, the bad, or the evil?",
keywords = "Cancer Research, Oncology, bleomycin, Freund adjuvant, gamma interferon, glycoprotein gp 100, granulocyte macrophage colony stimulating factor, interleukin 2, melan A, montanide isa 51, recombinant vaccine, survivin, synthetic peptide, tumor antigen, unclassified drug, cancer vaccine, adjuvant therapy, cancer immunization, CD4 CD8 ratio, CD8+ T lymphocyte, cell migration, clinical trial, delayed hypersensitivity, dose response, drug potentiation, electrochemotherapy, enzyme linked immunospot assay, human, letter, melanoma, multiple cycle treatment, peripheral lymphocyte, priority journal, protein expression, drug administration, immunology, note, skin tumor, Cancer Vaccines, CD8-Positive T-Lymphocytes, Drug Administration Schedule, Humans, Interleukin-2, Melanoma, Skin Neoplasms, ONCOLOGY, TUMOR-INFILTRATING LYMPHOCYTES, T-CELL RESPONSES, IDENTIFICATION, SURVIVIN",
author = "Andersen, {Mads Hald} and Hadrup, {Sine Reker} and Stratem, {Per thor} and Julie Gehl and Poul Geertsen and Becker, {J{\"u}rgen C.}",
year = "2005",
doi = "10.1200/JCO.2004.00.9837",
language = "English",
volume = "23",
pages = "5265--5267",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "22",
}
